Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges
Authors
Keywords
Small cell lung cancer, Immune checkpoint inhibitors, Immunotherapy, Tumor microenvironment, Combination therapy, Enhancer of zeste homolog 2
Journal
Journal for ImmunoTherapy of Cancer
Volume 7, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-08-05
DOI
10.1186/s40425-019-0690-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.
- (2019) Jonathan R. Strosberg et al. JOURNAL OF CLINICAL ONCOLOGY
- LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer
- (2019) Laura Bonanno et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
- (2018) Kent W. Mouw et al. BRITISH JOURNAL OF CANCER
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer
- (2018) Neil H. Segal et al. CLINICAL CANCER RESEARCH
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
- (2018) Giulia C. Leonardi et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
- (2018) Shirish M. Gadgeel et al. Journal of Thoracic Oncology
- Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung
- (2018) Hye Sook Kim et al. Journal of Thoracic Oncology
- Treatment of colon cancer with liver X receptor agonists induces immunogenic cell death
- (2018) Qiang Wang et al. MOLECULAR CARCINOGENESIS
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and γ-irradiation
- (2018) E. Zulato et al. BIOCHEMICAL PHARMACOLOGY
- The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes
- (2018) L. Bonanno et al. EUROPEAN JOURNAL OF CANCER
- Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies.
- (2018) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC).
- (2018) Daniel C. Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of pembrolizumab and paclitaxel in refractory extensive disease small cell lung cancer.
- (2018) YuJung Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC).
- (2018) Jonathan Wade Goldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.
- (2018) Hyun Cheol Chung et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer
- (2018) Kathryn C. Arbour et al. JOURNAL OF CLINICAL ONCOLOGY
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- LBA5Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
- (2018) M Reck et al. ANNALS OF ONCOLOGY
- 1664OA randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial
- (2018) J-L Pujol et al. ANNALS OF ONCOLOGY
- A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors
- (2018) Florence Atrafi et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
- (2018) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy
- (2018) Laura Bonanno et al. Journal of Thoracic Oncology
- Tumor-Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Non–Small Cell Lung Cancer
- (2017) B. Sepesi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The role of prophylactic cranial irradiation for patients with small-cell lung cancer
- (2017) Yoshiro Nakahara et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
- (2017) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Unravelling the biology of SCLC: implications for therapy
- (2017) Joshua K. Sabari et al. Nature Reviews Clinical Oncology
- Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome
- (2017) Paul Maddison et al. NEUROLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration
- (2017) X Zheng et al. ONCOGENE
- Treatment advances in small cell lung cancer (SCLC)
- (2017) Saiama N. Waqar et al. PHARMACOLOGY & THERAPEUTICS
- Antibody Isotypes for Tumor Immunotherapy
- (2017) Anna Kretschmer et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
- (2017) Hiro Sato et al. Nature Communications
- The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy
- (2017) Daniel Zingg et al. Cell Reports
- Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
- (2016) L.V. Sequist et al. ANNALS OF ONCOLOGY
- Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy
- (2016) Alfonso R. Sanchez-Paulete et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
- (2016) Edurne Arriola et al. Journal of Thoracic Oncology
- The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
- (2016) Andrew G. Nicholson et al. Journal of Thoracic Oncology
- The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer
- (2016) Roy M. Bremnes et al. Journal of Thoracic Oncology
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational signatures associated with tobacco smoking in human cancer
- (2016) L. B. Alexandrov et al. SCIENCE
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
- (2015) Hidenobu Ishii et al. Journal of Thoracic Oncology
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis
- (2015) Bin Shang et al. Scientific Reports
- Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study
- (2015) Paul Gozzard et al. PLoS One
- MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study
- (2014) Rita de Cássia S. Alves et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Impact of Paraneoplastic Cushing’s Syndrome in Small-Cell Lung Cancer
- (2014) Hélène Nagy-Mignotte et al. Journal of Thoracic Oncology
- Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells
- (2014) YIMIN LU et al. ONCOLOGY REPORTS
- Histologic Assessment of Tumor-Associated CD45 + Cell Numbers Is an Independent Predictor of Prognosis in Small Cell Lung Cancer
- (2013) Wei Wang et al. CHEST
- Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells
- (2013) Yuting Ma et al. IMMUNITY
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate
- (2012) Wei Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation